In March, CAS President, Dr Giuseppe Fuda, and CAS CEO Vanessa Foran, met with representatives from Environment and Climate Change Canada (ECCC). This included Dany Drouin (Director General of the Plastics and Waste Management Directorate) and Tracey Spack (Director, Plastics Regulatory Affairs Division).
Read More
CAS President, Dr. Giuseppe Fuda, and Chair of the Quality and Safety Committee, Dr. Conor Mc Donnell, provided joint input into Health Canada’s consultation on the Critical and Vulnerable Drug List in February. In their submission, they highlighted several critical drugs used in anesthesia and critical care, that were absent from the list.
Read More
To ensure CAS members' voices are heard ahead of the Ontario election expected in the coming months, CAS Board members and staff met with MPP France Gélinas, NDP Health Critic, and MPP Dr Adil Shamji, Liberal Health Critic. The discussions focused on HHR issues and CAS-proposed solutions.
Read More
Healthcare is a major contributor to this planetary crisis. The Canadian Anesthesiologists’ Society (CAS) firmly believes that all efforts should be made to reduce the impact of the healthcare sector on the environment while improving the quality of care.
Read More
This document accompanies the document Greening the OR: CAS Position Statement on
reducing harmful emissions, waste and costs and provides the rationale and evidence for
CAS’ recommendations.
Read More
We have received reports from anesthesiologists in Ontario regarding coring issues when
using BD Blunt needles to draw medications. Coring involves a small piece of the rubber
stopper detaching during needle insertion, which may lead to contamination or injection of
rubber fragments into patients.
Read More
On September 29, 2024, Baxter International (Baxter US) announced that its North Cove manufacturing facility in Marion, North Carolina, was damaged by flooding caused by Hurricane Helene.1 This U.S. facility mainly manufactures intravenous and peritoneal dialysis solutions. This facility was responsible for a significant proportion of the intravenous fluids supply in the United States.
Read More
Chloroprocaine was withdrawn from the Canadian market in 2012 due to a corporate decision by its manufacturer, citing a shortage of essential raw materials needed for production. However, chloroprocaine remained in production and widely available in the United States and Europe.
Read More